Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma

  • García-Domínguez, D. J.
  • Hajji, Nabil
  • Sánchez-Molina, Sara
  • Figuerola-Bou, Elisabet
  • Martínez de Pablos, Rocío
  • Espinosa-Oliva, Ana M.
  • Andrés-León, Eduardo
  • Terrón-Camero, Laura Carmen
  • Flores-Campos, Rocío
  • Pascual-Pasto, Guillem
  • Robles-Frías, María José
  • Machado, Isidro
  • Llombart-Bosch, Antonio
  • Magagnoli, Giovanna
  • Scotlandi, Katia
  • Carcaboso, Ángel M.
  • Mora, Jaume
  • Álava, Enrique de
  • Hontecillas-Prieto, Lourdes
Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor of children and young adults in which the principal driver is a fusion gene, EWSR1-FLI1. Although the essential role of EWSR1-FLI1 protein in the regulation of oncogenesis, survival, and tumor progression processes has been described in-depth, little is known about the regulation of chimeric fusion-gene expression. Here, we demonstrate that the active nuclear HDAC6 in EWS modulates the acetylation status of specificity protein 1 (SP1), consequently regulating the SP1/P300 activator complex binding to EWSR1 and EWSR1-FLI1 promoters. Selective inhibition of HDAC6 impairs binding of the activator complex SP1/P300, thereby inducing EWSR1-FLI1 downregulation and significantly reducing its oncogenic functions. In addition, sensitivity of EWS cell lines to HDAC6 inhibition is higher than other tumor or non-tumor cell lines. High expression of HDAC6 in primary EWS tumor samples from patients correlates with a poor prognosis in two independent series accounting 279 patients. Notably, a combination treatment of a selective HDAC6 and doxorubicin (a DNA damage agent used as a standard therapy of EWS patients) dramatically inhibits tumor growth in two EWS murine xenograft models. These results could lead to suitable and promising therapeutic alternatives for patients with EWS., Research in the E.D.A. lab is supported by Asociación Española Contra el Cáncer (AECC), the Ministry of Science of Spain-FEDER (CIBERONC, PI1700464, PI2000003, RD06/0020/0059)S. D.G.D. and L.H.P. are supported by CIBERONC (CB16/12/00361). D.G.D., M.J.R. and L.H.P. are PhD researchers funded by the Consejería de Salud, Junta de Andalucía (PI-0197-2016, ECAI F2-0012-2018 and PI-0013-2018, respectively)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

  • Garrido, Pilar|||0000-0002-5899-6125
  • Hladun, Raquel|||0000-0002-3191-1750
  • De Álava, Enrique|||0000-0001-8400-046X
  • Alvarez, Rosa|||0000-0003-0935-8298
  • Bautista, Francisco Jose|||0000-0002-0421-8862
  • López-Ríos, F.
  • Colomer, Ramon|||0000-0002-6393-3444
  • Rojo, F.
The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management of patients presenting with tumours with these alterations. Tumours that harbour NTRK fusions are found in both adults and children; and they are either rare tumours with common NTRK fusions that may be diagnostic, or more prevalent tumours with rare NTRK fusions. To assess currently available evidence on this matter, three key Spanish medical societies (the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Pathological Anatomy (SEAP), and the Spanish Society of Paediatric Haematology and Oncology (SEHOP) have brought together a group of experts to develop a consensus document that includes guidelines on the diagnostic, clinical, and therapeutic aspects of NTRK -fusion tumours. This document also discusses the challenges related to the routine detection of these genetic alterations in a mostly public Health Care System.